UNSPSC 51272402: Enflurane

This classification denotes an anesthetic agent with the molecular formula C3H2ClF5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 91I69L5AY5, chemically known as 2-chloro-1-(difluoromethoxy)-1,1,2-trifluoroethane but generally known as enflurane, which bears US NIH Compound Identifier 3226. European Medicines Agency schedules Enflurane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06530MIG.

UNSPSC 51272402 Enflurane, a Commodity code, does not reflect the actual scope of recent state and local procurement activity tagged under it. The three recent opportunities posted under this anesthetic-agent code involve naloxone procurement, direct-to-manufacturer pharmacy prescriptions, and generic multi-source pharmaceuticals and OTC products — none of which are enflurane or related inhalation anesthetics. This suggests either a persistent cataloging misalignment in state and local procurement systems or that the code is being used as a placeholder for broader pharmaceutical and medical-supply procurement when more granular categories are unavailable. The mismatch between the code's nominal scope and actual solicitations makes this code a low-value signal for firms seeking to bid on enflurane or other anesthetic gases.

The three opportunities span different issuing-body types and geographies. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries; the Texas Health and Human Services Commission posted an RFI (HHS0017013, due April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon. The MMCAP procurement is the largest in scope, requiring manufacturer compliance with cGMP, DSCSA, and FDA requirements, maintenance of $5 million in commercial general liability insurance, and a 3 percent administrative fee. Activity is concentrated in Florida, Texas, and Minnesota, with no enflurane-specific solicitations evident in the recent record.